LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones.

Oppenheimer analyst Leland Gershell upgraded Milestone Pharmaceuticals to Outperform from Perform with an $18 price target.